Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Near-term earnings momentum trade: stock rallied about 32% over 21 trading days and made a fresh window high, with Q2 2026 results due on 2026-07-23 as a potential catalyst.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Breakout hold ⢠Higher lows ⢠Pullback volatility Support Level: $33.00-$31.80 Resistance Level: $35.60 ATRC has trended higher over the last month, broke out and held gains, and remains constructive as long as it stays above $33.00 and clears $35.60 despite a sharp recent pullback.
Sentiment & News
Key News Insights: ⢠Double-digit growth ⢠EPS beat ⢠Segment weakness AtriCure posted strong Q2 2026 results with double-digit revenue growth, EPS well above estimates, and a return to GAAP profitability, though minimally invasive ablation remains a weak spot.
AI Summary
ATRC now looks like a genuine earnings-inflection story rather than just a growth med-tech name, as Q2's 13% revenue growth plus a sharp EPS beat and GAAP profitability suggest operating leverage is finally emerging, but the investment case still hinges on proving this margin expansion is durable while minimally invasive ablation remains a weak spot.
Description
AtriCure develops, manufactures and sells surgical systems and devices used to ablate cardiac tissue and intercostal nerves, serving hospitals and cardiac centers in the United States and internationally. Its portfolio includes radiofrequency and cryoablation systems, epicardial appendage occlusion and suture-based closure solutions, and a range of supporting instruments and disposables for electrophysiology and cardiac surgery. The company distributes products through a mix of independent distributors and direct sales teams and is headquartered in Mason, Ohio; it was incorporated in 2000.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 16 | Jul 23 | ATRC | AtriCure, Inc. | Near-term earnings momentum trade: stock rallied about 32% over 21 trading days and made a fresh window high, with Q2 2026 results due on 2026-07-23 as a potential catalyst. | Closed | -7.4% |
| Jan 12 | Jan 19 | ATRC | AtriCure, Inc. | AtriCure exhibits strong short-term growth supported by 16% revenue increase in Q3, positive EBITDA growth, cash flow improvement, clinical pipeline advancements, and strong technical breakout despite near-term technical softness. | Closed | +3.8% |